MedPath

Tagged News

Godavari Biorefineries Secures European Patent for Novel Anticancer Molecule Targeting Cancer Stem Cells

Oncology
  • Godavari Biorefineries Ltd has obtained a European patent for a novel anticancer molecule with proven efficacy against both cancer cells and cancer stem cells, validated in Spain, the UK, and under the Unitary Patent system.
  • The patented compound falls under the company's Anti-Cancer Research Segment and represents a significant advancement in targeting cancer stem cells, a crucial focus area in modern oncology research.
  • This patent milestone strengthens Godavari Biorefineries' global footprint in biotech innovation and reinforces its commitment to developing breakthrough solutions in cancer therapy.

AstraZeneca and Summit Therapeutics in Advanced Talks for $15 Billion Ivonescimab Licensing Deal

OncologyDrug Approval
  • AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.
  • The deal could include an upfront payment of several billion dollars plus milestone payments, representing one of the largest pharmaceutical licensing agreements in recent years.
  • Ivonescimab demonstrated statistically significant improvement in progression-free survival when combined with chemotherapy in previously treated lung cancer patients, though it failed to achieve statistical significance for overall survival.
  • Summit secured rights to ivonescimab through a $5 billion deal with China-based Akeso in 2022, and the drug is already approved in China as of May 2023.

Jacobio Pharma Receives IND Acceptance for BET Inhibitor JAB-8263 in Autoimmune Diseases

Oncology
  • Jacobio Pharma's Phase I/II IND application for BET inhibitor JAB-8263 in autoimmune diseases has been accepted by China's Center for Drug Evaluation, with review expected within 30 working days.
  • The oral BET inhibitor represents a potential breakthrough for autoimmune diseases, which affect 5%-9% of the global population and are currently treated primarily with intravenous monoclonal antibodies.
  • JAB-8263 previously demonstrated good tolerability in Phase I trials for solid tumors and hematological malignancies, with data presented at the 2024 ASH Annual Meeting.
  • This regulatory milestone marks Jacobio's expansion of JAB-8263 from oncology into autoimmune diseases, potentially benefiting a broader patient population with an oral therapeutic option.

Australia Opens First Antibody-Drug Conjugate Manufacturing Facility to Advance Precision Cancer Treatment

Precision MedicineOncology
  • IDT Australia has opened the nation's first facility dedicated to manufacturing antibody-drug conjugates (ADCs) for oncology therapies, establishing the Ehrlich Bioconjugation Centre in Victoria.
  • The facility represents a $3.8 million investment and will create 88 highly skilled local jobs while positioning Australia as a global leader in advanced cancer treatment manufacturing.
  • ADCs significantly improve patient survival rates and quality of life by delivering potent chemotherapy agents directly to cancer cells with high specificity, particularly benefiting breast cancer patients.
  • The global ADC market is forecast to reach US$140 billion over the next 15 years and is expected to displace 30-50% of the traditional chemotherapy market.

Lixte Biotechnology Secures $5 Million Private Placement to Advance Cancer Therapy Development

Oncology
  • Lixte Biotechnology Holdings completed a $5 million private placement on June 30, 2025, with proceeds designated for general corporate purposes and working capital to support ongoing cancer therapy development.
  • The company's lead compound LB-100, a first-in-class PP2A inhibitor, has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity and represents a pioneering approach in activation lethality cancer biology.
  • Proof-of-concept clinical trials for LB-100 are currently underway for colon, small cell lung, and sarcoma cancers, with the compound showing potential to enhance both chemotherapies and immunotherapies.

RedHill Biopharma Launches Precision Medicine Phase 2 Trial Combining Opaganib with Darolutamide for Advanced Prostate Cancer

Precision MedicineOncology
  • RedHill Biopharma has initiated patient recruitment for a Phase 2 study evaluating opaganib plus darolutamide in men with metastatic castrate-resistant prostate cancer, sponsored by ANZUP and supported by Bayer.
  • The innovative 60-patient trial uses a precision medicine approach with the PCPro lipid biomarker test to identify patients with poor prognosis who may benefit most from the combination therapy.
  • The study aims to overcome resistance to standard androgen receptor pathway inhibition treatment, with opaganib targeting three sphingolipid-metabolizing enzymes to enhance darolutamide efficacy.
  • Prostate cancer represents a significant global burden with 1.5 million new cases annually and a $12 billion market, making this precision medicine approach particularly valuable for advanced disease management.

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

NCT04207255Active, Not RecruitingPhase 2
Medical University of South Carolina
Posted 3/27/2020

Celltrion Advances Pembrolizumab Biosimilar Development as Herceptin Copy Nears European Launch

Monoclonal AntibodyDrug ApprovalOncology
  • Celltrion has initiated development of a biosimilar version of Merck's pembrolizumab (Keytruda), starting work 10 years ahead of the drug's patent expiration in June 2028.
  • The company's trastuzumab biosimilar Herzuma has gained EU approval and is expected to be priced up to 50% cheaper than Roche's subcutaneous Herceptin.
  • Biosimilar competitors will primarily target the intravenous Herceptin market, representing less than $1 billion in total European sales as most patients have switched to the more convenient subcutaneous formulation.

Sigvotatug Vedotin Shows Promise in NSCLC as Novel Integrin Beta-6 Targeted ADC Advances to Phase 3

Oncology
  • The novel integrin beta-6 directed antibody-drug conjugate sigvotatug vedotin demonstrated a confirmed overall response rate of 19.0% as monotherapy in NSCLC patients, with higher efficacy in nonsquamous, taxane-naive patients at 31.0%.
  • Combination therapy with pembrolizumab showed enhanced activity with a confirmed overall response rate of 42.9% in frontline NSCLC treatment, supporting the agent's potential for immune checkpoint inhibitor synergy.
  • The drug has advanced to the phase 3 Be6A Lung-01 trial comparing sigvotatug vedotin to docetaxel in previously treated NSCLC patients, bypassing phase 2 development due to encouraging early results.
  • Integrin beta-6 represents an attractive therapeutic target as it is minimally expressed in healthy tissues but upregulated in carcinogenesis and associated with poor prognosis in multiple cancer types.

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632RecruitingPhase 1
Seagen, a wholly owned subsidiary of Pfizer
Posted 6/8/2020

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401RecruitingPhase 3
Pfizer
Posted 7/23/2025

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Active, Not RecruitingNot Applicable
Seagen, a wholly owned subsidiary of Pfizer
Posted 2/21/2024

Avacta Strengthens Leadership Team with Appointment of Chief Medical Officer and Business Development Advisor

OncologyTargeted Therapy
  • Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline.
  • Liebowitz brings over 30 years of experience in oncology drug development and has contributed to more than 25 Investigational New Drug applications throughout his career.
  • The company also appointed Yulii Bogatyrenko as business development advisor to strengthen corporate growth strategy and pipeline advancement.
  • These appointments come at a pivotal time as Avacta continues to advance its pre|CISION platform for targeted oncology drug delivery.

FDA Clears IND for IKS014 HER2-Targeted ADC, Enabling US Clinical Trial Expansion

Oncology
  • The FDA has approved Iksuda Therapeutics' IND application for IKS014, a HER2-targeted antibody drug conjugate, allowing expansion of ongoing Phase 1 clinical trials to include US sites alongside existing locations in Australia, New Zealand, and Singapore.
  • Preliminary clinical data from the dose-escalation study demonstrates promising activity across multiple solid tumor types including breast, ovarian, gallbladder, and esophageal cancers, with notable efficacy in patients who relapsed after prior Enhertu treatment.
  • The Phase 1 trial is nearing completion of its dose-escalation phase and will proceed to expansion cohorts targeting HER2-positive breast cancer patients refractory to Enhertu, HER2-low breast cancer patients, and HER2-positive gastric cancer patients.
  • IKS014 utilizes a tumor-selective payload release mechanism with monomethyl auristatin F (MMAF) and showed impressive preclinical activity in both high- and low-HER2 expressing tumors with a favorable therapeutic index.

IKS014 in Advanced Solid Tumors That Express HER2

NCT05872295RecruitingPhase 1
Iksuda Therapeutics Ltd.
Posted 9/14/2023

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.